

DT Rec'd PCT/PTO 06 DEC 2004

INFORMATION DISCLOSURE  
CITATION

INTERNATIONAL PHASE OF INT'L APPLN. NO.

AT PCT NO.

PCT/US2003/18334

4061-28

APPLICANT

ZLOKOVIC

(Use several sheets if necessary)

FILING DATE

GROUP

December 6, 2004

Not Known

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DK	AR 5,958,883	09/1999	Snow			
↓	BR 6,011,019	01/2000	Thomas et al.			
↓	CR 6,140,309	10/2000	Thomas et al.			
↓	DR 2003/0171556	09/2003	Chae et al.			

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
ER					
FR					
GR					
HR					
IR					
JR					
KR					
LR					
MR					
NR					
OR					
PR					

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

DK	QR	Frippiat et al. "Subcytotoxic H <sub>2</sub> O <sub>2</sub> stress triggers a release of transforming growth factor-β1, which induces biomarkers of cellular senescence of human diploid fibroblasts" J. Biol. Chem. 276:2531-2537 (2001)
↓		Jones et al. "Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing" Nature Med. 5:1418-1423 (1999)
↓	RR	Kalaria et al. "Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia" Mol. Brain Res. 62:101-105 (1998)
↓		Solomon "Immunological approaches as therapy for Alzheimer's disease" Expert Opin. Biol. Ther. 2:907-917 (2002)
↓	SR	Tan et al. "Amyloidosis" Histopathol. 25:403-414 (1994)
↓	TR	Tarkowski et al. "Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia" Neurobiol. 23:237-243 (2002)
↓	UR	Vagnucci et al. "Alzheimer's disease and angiogenesis" Lancet 361:605-608 (2003)
	VR	
	WR	
	ZR	
	AAR	
	BBR	
	CCR	
	DDR	
	EER	


\*Examiner /Daniel Kolker/

Date Considered

03/21/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)


**INFORMATION DISCLOSURE  
CITATION**

 APPLN. NO.  
10/516,729  
APPLICANT

 ATTY. DKT. NO.  
4061-28

(Use several sheets if necessary)

**ZLOKOVIC**  
FILING DATE

 GROUP  
1647

December 6, 2004

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/DK/	AR	2004/0115671	06/2004	Zlokovic et al.		
/DK/	BR	2005/0170359	08/2005	Zlokovic		
	CR					
	DR					

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/DK/	ER	WO 02/057496	07/2002	WIPO		
	FR					
	GR					
	HR					
	IR					
	JR					
	KR					
	LR					
	MR					
	NR					
	OR					
	PR					

**OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)**

/DK/	QR	Chow et al. "Senescence of cerebral endothelium in Alzheimer's disease" 32 <sup>nd</sup> Annual Meeting of the Society for Neuroscience, Program 420.9 (2002)
	RR	Chow et al. "Gene expression profiles implicate vascular cell dysfunction in Alzheimer's disease" Society for Neuroscience Abstracts (31 <sup>st</sup> Annual Meeting) vol. 27, no. 2, pg. 2065 (2001)
	SR	de la Torre "Alzheimer disease as a vascular disorder. Nosological evidence" Stroke 33:1152-1162 (2002)-
	TR	Hofman et al. "Down regulation of GAX in cerebral endothelium in Alzheimer's disease" 32 <sup>nd</sup> Annual Meeting of the Society for Neuroscience, Program 328.2 (2002)
	UR	Kalaria et al. "The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease" Ann. N.Y. Academy of Sciences 893:113-125 (1999)
	VR	Kanagala et al. "Defective angiogenesis in Alzheimer's disease" 32 <sup>nd</sup> Annual Meeting of the Society for Neuroscience, Program 328.3 (2002)
	WR	Mackic et al. "Human blood-brain barrier receptors for Alzheimer's amyloid- $\beta$ 1-40" J. Clin. Invest. 102:734-743 (1998)
↓	ZR	Zlokovic et al. "Vascular disorder in Alzheimer's disease: Role in pathogenesis of dementia and therapeutic targets" Adv. Drug Delivery Rev. 54:1553-1559 (2002)

\*Examiner /Daniel Kolker/ Date Considered 03/21/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)